NOX66 and Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer - a Phase 1b Proof of Concept and Dose Confirmation Study
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Idronoxil (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Proof of concept
- Acronyms DARRT-1
- Sponsors Noxopharm
- 20 Sep 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 06 May 2020 Radiographic review assessing abscopal response results published in the Noxopharm Media Release.